Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.50 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4613765 | 0.88 | RIPK1 (0.48) | RIPK1UTS2RCNR2POLBHRH3 | |
| SCHEMBL24700138 | 0.82 | RIPK1 (0.52) | RIPK1CNR2 | |
| SCHEMBL28188380 | 0.81 | RIPK1 (0.47) | RIPK1UTS2R | |
| SCHEMBL4392356 | 0.78 | UTS2R (0.49) | RIPK1UTS2R | |
| SCHEMBL17558248 | 0.76 | RIPK1 (0.69) | RIPK1HSD11B1 | |
| SCHEMBL1853141 | 0.76 | RIPK1 (0.69) | RIPK1HSD11B1 | |
| SCHEMBL1847627 | 0.76 | RIPK1 (0.69) | RIPK1HSD11B1 | |
| SCHEMBL23139723 | 0.76 | RIPK1 (0.43) | RIPK1UTS2RCNR2HRH3 | |
| SCHEMBL23124099 | 0.75 | EPHX2 (0.67) | HRH3 | |
| SCHEMBL5968844 | 0.72 | RIPK1 (0.51) | RIPK1POLBSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| WO-2021055630-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL- BIOTECH INVESTMENTS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380314-A1 | SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, CLN6 | RIPK1 2840/4885UTS2R 2042/4885CNR2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.